|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatic Encephalopathy显示文摘 | Yurdaydin C Idilman R | 2012 | European Gastroenterology&Hepatology Review2012，7，4： | 1 |
| 2 | Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, bio- chemical, and serology outcomes through 96 weeks 显示文摘 | Sherman M Yurdaydin C Simsek H | 2008 | Hepatology2008，48，1： | 1 |
| 3 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2006 | Gastroenterology2006，130，7： | 1 |
| 4 | On-treatment decline in serum HBsAg levels predicts sustained immune control 1 year post-treatment, subsequent I-IBsAg clearance in HBeAg-negative hepatitis B virus- infected patients treated with peginterferon alfa-2a 显示文摘 | Marcellin P Piratvisuth T Brunetto M Bonino F Farci P Yurdaydin C Gurel S Kapprell HP Messinger D Popescu M | 2010 | Hepatol Int2010，4，： | 1 |
| 5 | Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B 显示文摘 | Brunetto MR Moriconi F Bonino F Lau GK Farci 19 Yurdaydin C Piratvisuth T Luo K Wang Y Hadziyannis S Wolf E McCloud P Batrla R Marcellin P | 2009 | Hepatology2009，49，4： | 1 |
| 6 | Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine显示文摘 | Bozkaya H Yurdaydin C T rtiner M | 2002 | Dig Dis Sci2002，47，8： | 1 |
| 7 | Budd-Chiari syndrome with multislice contrast enhanced three dimentional MR angiography显示文摘 | Erden A Karayalcin S Yurdaydin C | 2002 | ARJ2002，179，5： | 1 |
| 8 | Entecavir for treatment of lamivudine-refractory, HBeAg positive chronic hepatitis B 显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 9 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2006 | Gastroenterology2006，130，7： | 1 |
| 10 | Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B 显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
| 11 | Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks显示文摘 | Sherman M Yurdaydin C Simsek H | 2008 | Hepatology2008，45，1： | 1 |
| 12 | Cytotoxic CD4 T cells in viral hepatitis显示文摘 | Aslan N Yurdaydin C Wiegand J | 2006 | J Viral Hepat2006，13，8： | 1 |
| 13 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | | 0，，07： | 1 |
| 14 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，： | 1 |
| 15 | Quantitative HBsAg and HDV -RNA levels in chronic delta hepatitis显示文摘 | ZACHOU K YURDAYDIN C DREBBER LI | 2010 | Liver Int2010，30，3： | 1 |
| 16 | Entecavir is superior to continued lamivudine for the treatment of lamivudine-refractory,HBeAg( + ) chronic hepatitis B :Results of phase Ⅲ study ETV- 026 显示文摘 | SHERMAN M YURDAYDIN C SOLLANO J | 2004 | Hepatology2004，40，41： | 1 |
| 17 | Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients 显示文摘 | Marcellin P Bonino F Yurdaydin C | 2013 | Hepatol Int2013，7，1： | 1 |
| 18 | Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia显示文摘 | Bozkaya H Yurdaydin C Idilman R | 2005 | Antivir Ther2005，10，2： | 1 |
| 19 | Entecavir is superior to continued lamivudine for the treatment of lamivudine -refractory, HBsAg + chronic hepatitis B: Results of phase Ⅲ study ETV - 026 显示文摘 | Sherman M Yurdaydin C Sollano J | 2004 | Hepatol2004，40，4： | 1 |
| 20 | Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B显示文摘 | Sherman M Yurdaydin C Sollano J | 2006 | Gastroenterology2006，130，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员